Clinical Research Directory
Browse clinical research sites, groups, and studies.
Alpha-Lipoic Acid Supplementation and IVF Outcomes in Women of Advanced Maternal Age
Sponsor: Kaohsiung Veterans General Hospital.
Summary
Female fertility declines with advancing age, largely because of deteriorating oocyte quality driven by mitochondrial dysfunction and oxidative stress within the ovarian microenvironment. Alpha-lipoic acid (ALA) is a potent antioxidant that crosses cell and mitochondrial membranes, regenerates other antioxidants (vitamin C, vitamin E, glutathione, coenzyme Q10), and supports mitochondrial respiratory chain activity and ATP production. This prospective study will enroll 60 infertile women aged 35-45 years undergoing in vitro fertilization (IVF) treatment. Thirty participants will receive oral ALA 600 mg/day for two months before their IVF cycle, and thirty will proceed directly to IVF without supplementation. The study will compare oocyte and embryo quality, cumulus cell mitochondrial function and metabolic gene expression, and clinical pregnancy and live birth rates between the two groups.
Official title: Effects of Alpha-Lipoic Acid Supplementation on Oocyte Quality, Cumulus Cell Mitochondrial Function, and In Vitro Fertilization Outcomes in Infertile Women of Advanced Maternal Age: A Prospective Cohort Study
Key Details
Gender
FEMALE
Age Range
35 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-06-11
Completion Date
2028-06-30
Last Updated
2026-07-07
Healthy Volunteers
No
Interventions
Alpha-Lipoic Acid (ALA)
Oral Alpha-Lipoic Acid 600 mg/day for 2 months prior to IVF cycle initiation
Locations (1)
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan